HUTCHMED has announced the completion of patient enrollment in a Phase II trial for fanregratinib (HMPL-453), aimed at treating intrahepatic cholangiocarcinoma (IHCC) patients with FGFR2 fusion ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback